Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Articles by Krentz, A. J
	Search for Related Content

Social Bookmarking

	What's this?

Andrew J Krentz

Southampton University Hospitals NHS Trust, Southampton, General Hospital, Southampton, SO16 6YD, a.j.krentz{at}soton.ac.uk

References

Alberti KG Tight glycaemic control:the key to improving the management of type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:184-5.[Free Full Text]

Nice. Management of type 2 diabetes - management of blood pressure and blood lipids, October 2002.

Gale EA The myth of the metabolic syndrome. Diabetologia 2005;48: 1679-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Eckel RH, Grundy SM, Zimmet PZ The metabolic syndrome. Lancet 2005;365:1415-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.[Free Full Text]

Alexander CM, Landsman PB, Teutsch SM, Haffner SM NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-14.[Abstract/Free Full Text]

Malik S., Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.[Abstract/Free Full Text]

Wong ND Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. Br J Diabetes Vasc Dis 2005;5:305-14.[Abstract/Free Full Text]

Wild SH, Byrne CD Treatment of lipids to reduce cardiovascular disease risk among people with the metabolic syndrome or type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:315-19.[Abstract/Free Full Text]

Feher MD, Elkeles RS Fenofibrate in type 2 diabetes: The FIELD study. Br J Diabetes Vasc Dis 2005;5:330-3.[Free Full Text]

Van Gaal LF, Peiffer F., Ballaux D. Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid. Br J Diabetes Vasc Dis 2005;5:344-50.[Abstract/Free Full Text]

2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.[Abstract/Free Full Text]

Schachter M. Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts. Br J Diabetes Vasc Dis 2005;5:320-4.[Abstract/Free Full Text]

Williams B., Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Beevers DG The end 5. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet 2005;366:1510-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.[Abstract/Free Full Text]

Donnelly R. Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis 2005;5:325-9.[Abstract/Free Full Text]

Strippoli GF, Craig M., Deeks JJ, Schena FP, Craig JC Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.[Abstract/Free Full Text]

Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.[Abstract/Free Full Text]

Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]